Cargando…

Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells

Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a comm...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Hui-Ping, Lin, Ching-Yu, Hsiao, Ping-Hsuan, Wang, Horng-Dar, Sheng Jiang, Shih, Hsu, Jong-Ming, Jim, Wai-Tim, Chen, Marcelo, Kung, Hsing-Jien, Chuu, Chih-Pin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://www.ncbi.nlm.nih.gov/pubmed/24349321
http://dx.doi.org/10.1371/journal.pone.0082625
_version_ 1782295192734269440
author Lin, Hui-Ping
Lin, Ching-Yu
Hsiao, Ping-Hsuan
Wang, Horng-Dar
Sheng Jiang, Shih
Hsu, Jong-Ming
Jim, Wai-Tim
Chen, Marcelo
Kung, Hsing-Jien
Chuu, Chih-Pin
author_facet Lin, Hui-Ping
Lin, Ching-Yu
Hsiao, Ping-Hsuan
Wang, Horng-Dar
Sheng Jiang, Shih
Hsu, Jong-Ming
Jim, Wai-Tim
Chen, Marcelo
Kung, Hsing-Jien
Chuu, Chih-Pin
author_sort Lin, Hui-Ping
collection PubMed
description Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a commonly used cell line established from a human lymph node metastatic lesion of prostatic adenocarcinoma. We previously established two relapsed androgen receptor (AR)-rich androgen-independent LNCaP sublines 104-R1 (androgen depleted for 12 months) and 104-R2 cells (androgen depleted for 24 months) from AR-positive androgen-dependent LNCaP 104-S cells. LNCaP 104-R1 and 104-R2 mimics the AR-positive hormone-refractory relapsed tumors in patients receiving androgen ablation therapy. Androgen treatment stimulates proliferation of 104-S cells, but causes growth inhibition and G1 cell cycle arrest in 104-R1 and 104-R2 cells. We investigated the protein expression profile difference between LNCaP 104-S vs. LNCaP 104-R1, 104-R2, PC-3, and DU-145 cells as well as examined the sensitivity of these prostate cancer cells to different chemotherapy drugs and small molecule inhibitors. Compared to 104-S cells, 104-R1 and 104-R2 cells express higher protein levels of AR, PSA, c-Myc, Skp2, BCL-2, P53, p-MDM2 S166, Rb, and p-Rb S807/811. The 104-R1 and 104-R2 cells express higher ratio of p-Akt S473/Akt, p-EGFR/EGFR, and p-Src/Src, but lower ratio of p-ERK/ERK than 104-S cells. PC-3 and DU-145 cells express higher c-Myc, Skp2, Akt, Akt1, and phospho-EGFR but less phospho-Akt and phospho-ERK. Overexpression of Skp2 increased resistance of LNCaP cells to chemotherapy drugs. Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers. Our study provides rationale for targeting Akt, EGFR, Src, Bcl-2, and AR signaling as a treatment for AR-positive relapsed prostate tumors after hormone therapy.
format Online
Article
Text
id pubmed-3857776
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38577762013-12-12 Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells Lin, Hui-Ping Lin, Ching-Yu Hsiao, Ping-Hsuan Wang, Horng-Dar Sheng Jiang, Shih Hsu, Jong-Ming Jim, Wai-Tim Chen, Marcelo Kung, Hsing-Jien Chuu, Chih-Pin PLoS One Research Article Androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, 80-90% of the patients who receive androgen ablation therapy ultimately develop recurrent tumors in 12-33 months after treatment with a median overall survival time of 1-2 years after relapse. LNCaP is a commonly used cell line established from a human lymph node metastatic lesion of prostatic adenocarcinoma. We previously established two relapsed androgen receptor (AR)-rich androgen-independent LNCaP sublines 104-R1 (androgen depleted for 12 months) and 104-R2 cells (androgen depleted for 24 months) from AR-positive androgen-dependent LNCaP 104-S cells. LNCaP 104-R1 and 104-R2 mimics the AR-positive hormone-refractory relapsed tumors in patients receiving androgen ablation therapy. Androgen treatment stimulates proliferation of 104-S cells, but causes growth inhibition and G1 cell cycle arrest in 104-R1 and 104-R2 cells. We investigated the protein expression profile difference between LNCaP 104-S vs. LNCaP 104-R1, 104-R2, PC-3, and DU-145 cells as well as examined the sensitivity of these prostate cancer cells to different chemotherapy drugs and small molecule inhibitors. Compared to 104-S cells, 104-R1 and 104-R2 cells express higher protein levels of AR, PSA, c-Myc, Skp2, BCL-2, P53, p-MDM2 S166, Rb, and p-Rb S807/811. The 104-R1 and 104-R2 cells express higher ratio of p-Akt S473/Akt, p-EGFR/EGFR, and p-Src/Src, but lower ratio of p-ERK/ERK than 104-S cells. PC-3 and DU-145 cells express higher c-Myc, Skp2, Akt, Akt1, and phospho-EGFR but less phospho-Akt and phospho-ERK. Overexpression of Skp2 increased resistance of LNCaP cells to chemotherapy drugs. Paclitaxel, androgen, and inhibitors for PI3K/Akt, EGFR, Src, or Bcl-2 seem to be potential choices for treatment of advanced prostate cancers. Our study provides rationale for targeting Akt, EGFR, Src, Bcl-2, and AR signaling as a treatment for AR-positive relapsed prostate tumors after hormone therapy. Public Library of Science 2013-12-05 /pmc/articles/PMC3857776/ /pubmed/24349321 http://dx.doi.org/10.1371/journal.pone.0082625 Text en © 2013 Lin et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lin, Hui-Ping
Lin, Ching-Yu
Hsiao, Ping-Hsuan
Wang, Horng-Dar
Sheng Jiang, Shih
Hsu, Jong-Ming
Jim, Wai-Tim
Chen, Marcelo
Kung, Hsing-Jien
Chuu, Chih-Pin
Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title_full Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title_fullStr Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title_full_unstemmed Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title_short Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells
title_sort difference in protein expression profile and chemotherapy drugs response of different progression stages of lncap sublines and other human prostate cancer cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857776/
https://www.ncbi.nlm.nih.gov/pubmed/24349321
http://dx.doi.org/10.1371/journal.pone.0082625
work_keys_str_mv AT linhuiping differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT linchingyu differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT hsiaopinghsuan differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT wanghorngdar differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT shengjiangshih differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT hsujongming differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT jimwaitim differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT chenmarcelo differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT kunghsingjien differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells
AT chuuchihpin differenceinproteinexpressionprofileandchemotherapydrugsresponseofdifferentprogressionstagesoflncapsublinesandotherhumanprostatecancercells